([1-26](#_ENREF_1))

1. Gotsman, I., Shlomai, A., Alper, R., Rabbani, E., Engelhardt, D., and Ilan, Y. 2001. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect. *J Pharmacol Exp Ther* 297:926-932.

2. Shlomai, A., Trop, S., Gotsman, I., Jurim, O., Diment, J., Alper, R., Rabbani, E., Engelhardt, D., and Ilan, Y. 2001. Immunomodulation of experimental colitis: the role of NK1.1 liver lymphocytes and surrogate antigens--bystander effect. *J Pathol* 195:498-507.

3. Shlomai, A., and Shaul, Y. 2003. Inhibition of hepatitis B virus expression and replication by RNA interference. *Hepatology* 37:764-770.

4. Shlomai, A., Hershko, A.Y., Gabbay, E., and Ben-Chetrit, E. 2004. Clinical and radiographic features mimicking pulmonary embolism as the first manifestation of Takayasu's arteritis. *Clin Rheumatol* 23:470-472.

5. Shlomai, A., and Shaul, Y. 2004. RNA interference--small RNAs effectively fight viral hepatitis. *Liver Int* 24:526-531.

6. Shlomai, A., Paran, N., and Shaul, Y. 2006. PGC-1alpha controls hepatitis B virus through nutritional signals. *Proc Natl Acad Sci U S A* 103:16003-16008.

7. Shlomai, A., and Shaul, Y. 2008. The "metabolovirus" model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon. *Med Hypotheses* 71:53-57.

8. Shlomai, A., Lubelsky, Y., Har-Noy, O., and Shaul, Y. 2009. The "Trojan horse" model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector. *Biochem Biophys Res Commun* 390:619-623.

9. Shlomai, A., and Shaul, Y. 2009. The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription. *Biochem Biophys Res Commun* 381:544-548.

10. Rechtman, M.M., Har-Noy, O., Bar-Yishay, I., Fishman, S., Adamovich, Y., Shaul, Y., Halpern, Z., and Shlomai, A. 2010. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. *FEBS Lett* 584:2485-2490.

11. Shlomai, A., and Guzner-Gur, H. 2010. Ectopic splenomegaly. *Intern Med J* 40:600.

12. Shlomai, A., Kariv, R., Leshno, M., Beth-or, A., Sheinberg, B., and Halpern, Z. 2010. Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus. *J Gastroenterol Hepatol* 25:1687-1691.

13. Shlomai, A., Nutman, A., Kotlovsky, T., Schechner, V., Carmeli, Y., and Guzner-Gur, H. 2010. Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome. *Isr Med Assoc J* 12:622-627.

14. Bar-Yishay, I., Shaul, Y., and Shlomai, A. 2011. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression. *Liver Int* 31:282-290.

15. Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., and Fishman, S. 2011. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. *J Hepatol* 54:1214-1223.

16. Tchebiner, J.Z., Nutman, A., Boursi, B., Shlomai, A., Sella, T., Wasserman, A., and Guzner-Gur, H. 2011. Diagnostic and prognostic value of thrombocytosis in admitted medical patients. *Am J Med Sci* 342:395-401.

17. Zelber-Sagi, S., Yeshua, H., Shlomai, A., Blendis, L., Leshno, M., Levit, S., Halpern, Z., and Oren, R. 2011. Sampling variability of transient elastography according to probe location. *Eur J Gastroenterol Hepatol* 23:507-514.

18. Ben-Shlomo, S., Einstein, F.H., Zvibel, I., Atias, D., Shlomai, A., Halpern, Z., Barzilai, N., and Fishman, S. 2012. Perinephric and epididymal fat affect hepatic metabolism in rats. *Obesity (Silver Spring)* 20:151-156.

19. Ben-Shlomo, S., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E.M., Halpern, Z., Oren, R., and Fishman, S. 2012. Erratum to: Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. *Dig Dis Sci*.

20. Shlomai, A. 2012. Targeting late SV40 factor: Is the achilles heel of hepatocarcinogenesis revealed? *World J Gastroenterol* 18:6709-6711.

21. Shlomai, A., Rechtman, M.M., Burdelova, E.O., Zilberberg, A., Hoffman, S., Solar, I., Fishman, S., Halpern, Z., and Sklan, E.H. 2012. The metabolic regulator PGC-1alpha links hepatitis C virus infection to hepatic insulin resistance. *J Hepatol* 57:867-873.

22. Shlomo, S.B., Zvibel, I., Rabinowich, L., Goldiner, I., Shlomai, A., Santo, E.M., Halpern, Z., Oren, R., and Fishman, S. 2012. Dipeptidyl Peptidase 4-Deficient Rats Have Improved Bile Secretory Function in High Fat Diet-Induced Steatosis. *Dig Dis Sci*.

23. Sikuler, E., Ackerman, Z., Braun, M., Baruch, Y., Bruck, R., Safadi, R., Shlomai, A., and Ben-Ari, Z. 2012. [Guidelines for diagnosis and management of cirrhotic ascites and its complications. The Israeli Association for the Study of the Liver]. *Harefuah* 151:705-708, 719.

24. Zelber-Sagi, S., Lotan, R., Shlomai, A., Webb, M., Harrari, G., Buch, A., Nitzan Kaluski, D., Halpern, Z., and Oren, R. 2012. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. *J Hepatol* 56:1145-1151.

25. Mouler Rechtman, M., Burdelova, E.O., Bar-Yishay, I., Ben-Yehoyada, M., Fishman, S., Halpern, Z., and Shlomai, A. 2013. The metabolic regulator PGC-1alpha links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus. *J Viral Hepat* 20:34-41.

26. Shlomai, A., Halfon, P., Goldiner, I., Zelber-Sagi, S., Halpern, Z., Oren, R., and Bruck, R. 2013. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. *J Viral Hepat* 20:95-102.

27. Adamovich, Y., Shlomai, A., Tsvetkov, P., Umansky, K.B., Reuven, N., Estall, J.L., Spiegelman, B.M., and Shaul, Y. 2013. The protein level of PGC-1alpha, a key metabolic regulator, is controlled by NADH-NQO1. *Mol Cell Biol*.